Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Mats Hidestrand PhD

Mats Hidestrand PhD

Assistant Adjunct Professor

Institution: Medical College of Wisconsin
Department: Surgery
Division: Pediatric Congenital Cardiac Surgery
Program: Pediatric Cardiothoracic-Mitchell Research


  • Non-invasive prenatal detection of trisomy 21 using tandem single nucleotide polymorphisms. (Ghanta S, Mitchell ME, Ames M, Hidestrand M, Simpson P, Goetsch M, Thilly WG, Struble CA, Tomita-Mitchell A) PLoS One 2010 Oct 08;5(10):e13184 PMID: 20949031 PMCID: PMC2951898 10/16/2010
  • Sca-1-expressing nonmyogenic cells contribute to fibrosis in aged skeletal muscle. (Hidestrand M, Richards-Malcolm S, Gurley CM, Nolen G, Grimes B, Waterstrat A, Zant GV, Peterson CA) J Gerontol A Biol Sci Med Sci 2008 Jun;63(6):566-79 PMID: 18559630 PMCID: PMC2755567 06/19/2008
  • Chronic ethanol consumption inhibits postlactational anabolic bone rebuilding in female rats. (Shankar K, Hidestrand M, Liu X, Chen JR, Haley R, Perrien DS, Skinner RA, Lumpkin CK Jr, Badger TM, Ronis MJ) J Bone Miner Res 2008 Mar;23(3):338-49 PMID: 17967133 10/31/2007
  • A novel mouse model for the study of the inhibitory effects of chronic ethanol exposure on direct bone formation. (Wahl EC, Liu L, Perrien DS, Aronson J, Hogue WR, Skinner RA, Hidestrand M, Ronis MJ, Badger TM, Lumpkin CK Jr) Alcohol 2006 Jul;39(3):159-67 PMID: 17127135 11/28/2006
  • Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaB ligand in osteoblasts. (Chen JR, Haley RL, Hidestrand M, Shankar K, Liu X, Lumpkin CK, Simpson PM, Badger TM, Ronis MJ) J Pharmacol Exp Ther 2006 Dec;319(3):1182-90 PMID: 16971503 09/15/2006
  • Physiologic and genomic analyses of nutrition-ethanol interactions during gestation: Implications for fetal ethanol toxicity. (Shankar K, Hidestrand M, Liu X, Xiao R, Skinner CM, Simmen FA, Badger TM, Ronis MJ) Exp Biol Med (Maywood) 2006 Sep;231(8):1379-97 PMID: 16946407 09/02/2006
  • Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. (Keizers PH, Schraven LH, de Graaf C, Hidestrand M, Ingelman-Sundberg M, van Dijk BR, Vermeulen NP, Commandeur JN) Biochem Biophys Res Commun 2005 Dec 16;338(2):1065-74 PMID: 16269134 11/05/2005
  • Different molecular mechanisms underlie ethanol-induced bone loss in cycling and pregnant rats. (Shankar K, Hidestrand M, Haley R, Skinner RA, Hogue W, Jo CH, Simpson P, Lumpkin CK Jr, Aronson J, Badger TM, Ronis MJ) Endocrinology 2006 Jan;147(1):166-78 PMID: 16239303 10/22/2005
  • The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. (Lussenburg BM, Keizers PH, de Graaf C, Hidestrand M, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN) Biochem Pharmacol 2005 Oct 15;70(8):1253-61 PMID: 16135359 09/02/2005
  • The effects of pregnancy on ethanol clearance. (Badger TM, Hidestrand M, Shankar K, McGuinn WD, Ronis MJ) Life Sci 2005 Sep 9;77(17):2111-26 PMID: 15925387 06/01/2005
  • Effects of light and dark beer on hepatic cytochrome P-450 expression in male rats receiving alcoholic beverages as part of total enteral nutrition. (Hidestrand M, Shankar K, Ronis MJ, Badger TM) Alcohol Clin Exp Res 2005 May;29(5):888-95 PMID: 15897735 05/18/2005
  • Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. (Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S) Toxicol In Vitro 2005 Aug;19(5):621-9 PMID: 15893449 05/17/2005
  • Use of molecular simulation for mapping conformational CYP2E1 epitopes. (Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, Rolla R, Occhino G, Albano E, Ingelman-Sundberg M) J Biol Chem 2004 Dec 3;279(49):50949-55 PMID: 15456790 10/01/2004
  • Identification of sequences responsible for intracellular targeting and membrane binding of rat CYP2E1 in yeast. (Neve EP, Hidestrand M, Ingelman-Sundberg M) Biochemistry 2003 Dec 16;42(49):14566-75 PMID: 14661969 12/10/2003
  • Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. (Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O) Drug Metab Dispos 2003 Sep;31(9):1093-102 PMID: 12920164 08/16/2003
  • Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. (Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML) Eur J Clin Pharmacol 2003 Jun;59(2):103-9 PMID: 12684728 04/10/2003
  • Recent Progress in Drug Metabolism Research. (Aklillu E, Hidestrand M, Ingelman-Sundberg M, Malmebo S, Westlind A) Drug News Perspect 2002 Oct;15(8):528-534 PMID: 12677192 04/05/2003
  • Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. (Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M) Mol Pharmacol 2002 Mar;61(3):586-94 PMID: 11854439 02/21/2002
  • The importance of residues in substrate recognition site 3 for the catalytic function of CYP2D25 (vitamin D 25-hydroxylase). (Hosseinpour F, Hidestrand M, Ingelman-Sundberg M, Wikvall K) Biochem Biophys Res Commun 2001 Nov 9;288(4):1059-63 PMID: 11689019 11/02/2001
  • CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. (Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M) Drug Metab Dispos 2001 Nov;29(11):1480-4 PMID: 11602525 10/17/2001
  • Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. (Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G) Drug Metab Dispos 2001 Oct;29(10):1263-8 PMID: 11560868 09/19/2001
  • Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. (Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF) Xenobiotica 2001 Jun;31(6):321-43 PMID: 11513246 08/22/2001
  • Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. (Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M) Pharmacogenetics 2001 Jul;11(5):417-27 PMID: 11470994 07/27/2001
  • Role of CYP2C9 polymorphism in losartan oxidation. (Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E) Drug Metab Dispos 2001 Jul;29(7):1051-6 PMID: 11408373 06/16/2001
  • Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. (Facciolá G, Hidestrand M, von Bahr C, Tybring G) Eur J Clin Pharmacol 2001 Mar;56(12):881-8 PMID: 11317475 04/25/2001
  • An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. (Andersson TB, Sjöberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Goldfarb PS, Lewis DF, Corcos L, Guillouzo A, Taavitsainen P, Pelkonen O) Drug Metab Dispos 2001 May;29(5):712-20 PMID: 11302938 04/17/2001
  • Cloning and expression of rat CYP2E1 in Saccharomyces cerevisiae: detection of genotoxicity of N-alkylformamides. (Del Carratore MR, Mezzatesta C, Hidestrand M, Neve P, Amato G, Gervasi PG) Environ Mol Mutagen 2000;36(2):97-104 PMID: 11013407 10/03/2000
  • Characterization and functional analysis of two common human cytochrome P450 1B1 variants. (McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, Ingelman-Sundberg M) Arch Biochem Biophys 2000 Jun 1;378(1):175-81 PMID: 10871058 06/28/2000
  • Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. (Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH) J Biol Chem 2000 Jul 21;275(29):21844-9 PMID: 10791960 05/03/2000
  • A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. (Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M) Mol Pharmacol 1997 Dec;52(6):1034-40 PMID: 9415713 01/13/1998
  • Last update: 12/30/2010
    jenkins-FCD Prod-29 84643b21e512b06ca32a9eea21e90ce5435f61b4